{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:30Z","timestamp":1792801650641,"version":"4.5.0"},"reference-count":21,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T00:00:00Z","timestamp":1271116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Efavirenz\u2010based HIV therapy is associated with breast hypertrophy and gynaecomastia. Here, we tested the hypothesis that efavirenz induces gynaecomastia through direct binding and modulation of the oestrogen receptor (ER).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To determine the effect of efavirenz on growth, the oestrogen\u2010dependent, ER\u2010positive breast cancer cell lines MCF\u20107, T47D and ZR\u201075\u20101 were treated with efavirenz under oestrogen\u2010free conditions in the presence or absence of the anti\u2010oestrogen ICI 182,780. Cells treated with 17\u03b2\u2010oestradiol in the absence or presence of ICI 182,780 served as positive and negative controls, respectively. Cellular growth was assayed using the crystal violet staining method and an <jats:italic>in vitro<\/jats:italic> receptor binding assay was used to measure the ER binding affinity of efavirenz.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Efavirenz induced growth in MCF\u20107 cells with an estimated effective concentration for half\u2010maximal growth (EC<jats:sub>50<\/jats:sub>) of 15.7\u2003\u03bcM. This growth was reversed by ICI 182,780. Further, efavirenz binds directly to the ER [inhibitory concentration for half maximal binding (IC<jats:sub>50<\/jats:sub>) of \u223c52\u2003\u03bcM] at a roughly 1000\u2010fold higher concentration than observed with 17\u03b2\u2010oestradiol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data suggest that efavirenz\u2010induced gynaecomastia may be caused, at least in part, by drug\u2010induced ER activation in breast tissues.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2010.00831.x","type":"journal-article","created":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T01:50:38Z","timestamp":1271123438000},"page":"603-607","source":"Crossref","is-referenced-by-count":25,"title":["Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth"],"prefix":"10.1111","volume":"11","author":[{"given":"MJ","family":"Sikora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JM","family":"Rae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MD","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Desta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02854-3"},{"key":"e_1_2_6_4_2","first-page":"555","article-title":"Antiretroviral treatment of adult HIV infection","volume":"300","author":"Hammer SM","year":"2008","journal-title":"2008 recommendations of the International AIDS Society-USA panel"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00011"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629100-00004"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107270-00018"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00021"},{"key":"e_1_2_6_9_2","first-page":"23","article-title":"A case\u2010control study of gynecomastia in HIV\u20101\u2010infected patients receiving HAART","volume":"14","author":"Rahim S","year":"2004","journal-title":"AIDS Read"},{"key":"e_1_2_6_10_2","first-page":"492","article-title":"Efavirenz versus nevirapine in current clinical practice","volume":"35","author":"Manfredi R","year":"2004","journal-title":"a prospective, open-label observational study"},{"key":"e_1_2_6_11_2","first-page":"244","article-title":"Efavirenz\u2010associated gynecomastia","volume":"10","author":"Jover F","year":"2004","journal-title":"report of five cases and review of the literature"},{"key":"e_1_2_6_12_2","first-page":"511","article-title":"Gynaecomastia in HIV\u2010infected men on highly active antiretroviral therapy","volume":"9","author":"Mira JA","year":"2004","journal-title":"association with efavirenz and didanosine treatment"},{"key":"e_1_2_6_13_2","first-page":"289","article-title":"The androgen metabolite 5alpha\u2010androstane\u20103beta,17beta\u2010diol (3betaAdiol) induces breast cancer growth via estrogen receptor","volume":"115","author":"Sikora MJ","year":"2009","journal-title":"implications for aromatase inhibitor resistance"},{"key":"e_1_2_6_14_2","first-page":"267","article-title":"Efavirenz plasma concentrations in HIV\u2010infected patients","volume":"26","author":"Stahle L","year":"2004","journal-title":"inter- and intraindividual variability and clinical effects"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100517"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181b327ca"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1258\/095646202760159756"},{"key":"e_1_2_6_18_2","first-page":"295","article-title":"Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer","volume":"6","author":"Perdona S","year":"2005","journal-title":"a randomised controlled trial"},{"key":"e_1_2_6_19_2","first-page":"106","article-title":"Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150\u2003mg monotherapy in patients with prostate cancer","volume":"52","author":"Fradet Y","year":"2007","journal-title":"a randomised, placebo-controlled, dose-response study"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:BREA.0000025406.31193.e8"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-1483-4"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:BREA.0000010702.10130.29"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2010.00831.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2010.00831.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T21:03:27Z","timestamp":1698699807000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2010.00831.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,3]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1468-1293.2010.00831.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2010.00831.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,3]]}}}